Schizophrenia and Psychoses Archive

Quality of Diabetes Care Low Among Patients With Schizophrenia

Quality of Diabetes Care Low Among Patients With Schizophrenia

The quality of diabetes care was examined in patients with and without schizophrenia in a Danish nationwide cohort.

Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse

Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse

In patients with schizophrenia, long-acting injectable formulations of paliperidone palmitate delay relapse significantly after withdrawal.

Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia

Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia

Dopamine dysfunction underlies the pathoetiology of psychosis in both bipolar disorder and schizophrenia.

Predictors of Development of Early Onset Psychosis in Parkinson Disease

Predictors of Development of Early Onset Psychosis in Parkinson Disease

Researchers conducted a prospective case-control study to examine predictors of early and late-onset psychosis in Parkinson disease.

Persistent Negative Symptoms in First-Episode Psychosis Associated With Early Onset of Disease

Persistent Negative Symptoms in First-Episode Psychosis Associated With Early Onset of Disease

These findings suggest that there are critical periods of development associated with a higher risk of persistent negative symptoms.

New Performance-Based Tool Evaluates Cognitive Impact of Schizophrenia

New Performance-Based Tool Evaluates Cognitive Impact of Schizophrenia

In this study, 672 patients with schizophrenia were evaluated with the EPICOG-SCH brief cognitive battery.

Signs of Schizophrenia That Should Not Be Ignored

Signs of Schizophrenia That Should Not Be Ignored

Seven signs and symptoms might alert someone to the possible presentation of schizophrenia.

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

The FDA issued a refusal to file letter for a new drug application.

Paliperidone Inadequate Responders May Benefit from Switch to Aripiprazole Lauroxil ER

Paliperidone Inadequate Responders May Benefit from Switch to Aripiprazole Lauroxil ER

Switching therapy to Aristada resulted in statistically significant and clinically meaningful improvement in schizophrenia symptoms.

Adjunctive Telmisartan's Effects on Symptoms of Schizophrenia

Adjunctive Telmisartan's Effects on Symptoms of Schizophrenia

Adding telmisartan to treatment with olanzapine or clozapine may improve symptoms of schizophrenia.

Why Do Antipsychotics Cause Weight Gain?

Why Do Antipsychotics Cause Weight Gain?

Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.

Long-Term Cariprazine Safe, Tolerable for Schizophrenia

Long-Term Cariprazine Safe, Tolerable for Schizophrenia

Long-term treatment of schizophrenia with cariprazine was found to be both safe and well-tolerated.

Increased Psychotic Symptoms in Offspring of Patients With Schizophrenia

Increased Psychotic Symptoms in Offspring of Patients With Schizophrenia

Children and adolescent offspring of patients with schizophrenia demonstrate more attenuated psychotic symptoms.

Liraglutide Improves Cardiometabolic Disturbances in Schizophrenia Tx With Clozapine

Liraglutide Improves Cardiometabolic Disturbances in Schizophrenia Tx With Clozapine

Glucose tolerance and body mass index in patients with schizophrenia were improved by liraglutide.

Negative Symptoms In Schizophrenia Reduced By Novel Therapy

Negative Symptoms In Schizophrenia Reduced By Novel Therapy

Patients with schizophrenia in the MIN-101 trial demonstrated lower negative factor scores than a placebo group.

Memory Training Opportunities Exist for Patients With Schizophrenia

Memory Training Opportunities Exist for Patients With Schizophrenia

Impaired recollection could be a vulnerability marker for schizophrenia, whereas impaired social context memory could be a disease-related marker.

Long-acting Antipsychotics: Better Efficacy in Some Outcomes for Schizophrenia

Long-acting Antipsychotics: Better Efficacy in Some Outcomes for Schizophrenia

Schizophrenia treatment with long-acting injectable antipsychotic agents resulted in lower rehospitalization rates.

Clozapine as Causal Agent in Gastrointestinal Hypomotility Events

Clozapine as Causal Agent in Gastrointestinal Hypomotility Events

Clozapine-induced gastrointestinal hypomotility is a medical emergency that requires urgent attention.

Results for Patients With Schizophrenia Who Transition to PP3M

Results for Patients With Schizophrenia Who Transition to PP3M

A high percentage of patients were persistent and adherent to their PP3M treatment.

Clozapine Protects Patients With Tx-resistant Schizophrenia Against Self-harm

Clozapine Protects Patients With Tx-resistant Schizophrenia Against Self-harm

Clozapine might lower risk of self-harm for patients with treatment-resistant schizophrenia.

Mental Illness Leads to Higher Prevalence of Blood Viruses

Mental Illness Leads to Higher Prevalence of Blood Viruses

HIV, hepatitis B and hepatitis C are more common among patients with mental illnesses.

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

Long-acting injectables should be considered earlier in the treatment of schizophrenia.

Childhood Maltreatment Associated With Increased Risk of Psychosis in Ultra-High Risk Individuals

Childhood Maltreatment Associated With Increased Risk of Psychosis in Ultra-High Risk Individuals

Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

Concomitant SSRI/SNRI use was associated with an increased diabetes risk in AAP-treated young people.

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

There is currently no approved drug combination for treatment-resistant schizophrenia.

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

In patients with schizophrenia being treated with clozapine or olanzapine, liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances.

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

Electroconvulsive therapy can be a clinically effective treatment for patients with severe forms of schizophrenia.

Late Teen Emotional Stability Inversely Tied to Mental Illness

Late Teen Emotional Stability Inversely Tied to Mental Illness

Emotional stability assessed in late adolescence is inversely associated with serious mental illness.

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

Long-term valbenazine may be beneficial in managing tardive dyskinesia.

BMI In Schizophrenia Patients Associated With C-reactive Protein

BMI In Schizophrenia Patients Associated With C-reactive Protein

Body mass index in patients with schizophrenia is linked to C-reactive protein.

Metabolic, Endocrine Profiles Examined in Long-term Schizophrenia Therapy

Metabolic, Endocrine Profiles Examined in Long-term Schizophrenia Therapy

Schizophrenia outpatients were examined in this 52-week open-label extension trial.

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.

Antipsychotic Symptoms Persist for Patients Seeking Treatment

Antipsychotic Symptoms Persist for Patients Seeking Treatment

Dopamine-blocking antipsychotics are ineffective right from the onset of illness.

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.

Antipsychotic Nonadherence Due to Social Stigma

Antipsychotic Nonadherence Due to Social Stigma

Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.

Antipsychotic Side Effect Treatment Gets FDA Approval

Antipsychotic Side Effect Treatment Gets FDA Approval

Ingrezza significantly and rapidly improved tardive dyskinesia symptoms compared to placebo, rmarking a tremendous breakthrough for patients suffering from TD.

Schizophrenia Risk Linked to Cannabis Use

Schizophrenia Risk Linked to Cannabis Use

Cannabis is the most widely misused illicit drug.

Schizophrenia Associated With Years of Life Lost

Schizophrenia Associated With Years of Life Lost

Schizophrenia was associated with 13 to 15 years of potential life lost.

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.

Antipsychotic Adherence Boosted by Financial Incentives

Antipsychotic Adherence Boosted by Financial Incentives

A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.

Schizophrenia Symptom Improvements and Adverse Effects

Schizophrenia Symptom Improvements and Adverse Effects

Participants in the risperidone group were generally more likely to achieve a significant clinical improvement in their mental state.

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

Schizophrenia Treatment Outcomes Favor Cariprazine Over Risperidone

Cariprazine treatment led to greater improvement in the negative symptoms of schizophrenia than risperidone.

Schizophrenia Symptoms Reduced by Vitamin B

Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.

FDA Approves New Schizophrenia Treatment for Adolescents

FDA Approves New Schizophrenia Treatment for Adolescents

The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Researchers profiled which young people may do well after first-episode psychosis without medication.

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

Childhood Trauma, Depression Associated With Impaired Quality of Life in Schizophrenia

Targeting negative symptoms in patients with schizophrenia may be more effective in improving patients' QoL.

Cardiometabolic Factors in Youth Schizophrenia Treatment

Cardiometabolic Factors in Youth Schizophrenia Treatment

Pretreatment cardiometabolic status to be taken into consideration for treatment of first episode psychosis.

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

Facial Affect Recognition Training Improves Social Outcomes in Psychosis

Inability to interpret facial expressions may exacerbate psychotic symptoms, either indirectly via social defeat or directly by creating confusing interpersonal experiences.

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

Pediatric Patients Should Undergo Electrocardiogram Assessment Before Antipsychotic Treatment

Cardiac safety is integral to child and adolescent antipsychotic therapy.

Schizophrenia Linked to Type 2 Diabetes

Schizophrenia Linked to Type 2 Diabetes

Patients with early schizophrenia may have already started down the road to diabetes, even prior to actual diagnosis.

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

Antipsychotic Switching in Schizophrenia: Immediate vs Gradual Discontinuation

Both immediate and gradual discontinuation of the current antipsychotic medication are viable treatment options.

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

First-Episode Schizophrenia Approaches Aided by Guidelines Instrument

Clinical practice guidelines are important resources for early intervention in a first episode of schizophrenia.

Predictors of Favorable Outcomes in First-Episode Psychosis Without Medication

Predictors of Favorable Outcomes in First-Episode Psychosis Without Medication

Young patients with first-episode psychosis may be able to achieve recovery.

Schizophrenia Patient Dead After UTI Treatment

Schizophrenia Patient Dead After UTI Treatment

This case offers evidence of the interaction between ciprofloxacin and clozapine.

Mindfulness Intervention Effective for Distressing Voices in Psychosis

Mindfulness Intervention Effective for Distressing Voices in Psychosis

Combined cognitive therapy and mindfulness can have lasting positive effects on behavior and mood.

Underlying Mechanism of Auditory Impairment in Schizophrenia Reveals Potential Therapeutic Path

Underlying Mechanism of Auditory Impairment in Schizophrenia Reveals Potential Therapeutic Path

Benefits of NMDA receptor agonists in patients with schizophrenia include improvements with memory and reading.

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

No Difference Between Omega-3 & Placebo in Patients at Ultrahigh Risk for Psychosis

PUFA supplementation offers little additional aid to psychosis when good psychosocial care is already sought.

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

Prolactin-Related Symptoms Decrease with Reduced Risperidone Dosage

Hyperprolactinemia should be monitored during long-term risperidone treatment.

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Efficacy of Lurasidone Assessed in Adolescents With Schizophrenia

Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

Impaired Auditory 40-Hz Steady-State Responses Noted in Schizophrenia

40-Hz ASSR spectral power and phase-locking deficits could be useful probes for assessing circuit dysfunctions in the disorder.

Prediabetic Markers May Be Linked With First-Episode Psychosis

Prediabetic Markers May Be Linked With First-Episode Psychosis

The findings might help to explain the increased prevalence of type 2 diabetes in patients with schizophrenia.

Significant Cognitive Impairment in Those At High Risk of Psychosis

Significant Cognitive Impairment in Those At High Risk of Psychosis

Studying cognition deficits during the clinical high risk period allows researchers to observe cognitive defects before chronicity and long-term medication use obscure the core deficits.

Psych Meds Rx May Reduce Violent Reoffending in Ex-Prisoners

Psych Meds Rx May Reduce Violent Reoffending in Ex-Prisoners

Medications used to treat addiction cut the risk of reoffending in half.

Heart Rate, BP in Male Teens Linked to Risk for Psych Disorders

Heart Rate, BP in Male Teens Linked to Risk for Psych Disorders

Indicators of schizophrenia, obsessive-compulsive disorder, and anxiety might be spotted in physical symptoms at age 18.

The Effect of Cognitive Remediation Training on Functional Connectivity and Social Cognition in Schizophrenia

The Effect of Cognitive Remediation Training on Functional Connectivity and Social Cognition in Schizophrenia

Study provides further evidence for the effects of cognitive enhancement intervention on brain functional connectivity and cognitive performance in patients with schizophrenia.

Gene Expression Patterns in Polygenic Schizophrenia Risk

Gene Expression Patterns in Polygenic Schizophrenia Risk

Data indicate that 693 genes are differentially expressed between individuals diagnosed with schizophrenia and typical, healthy controls.

Ambiguity Aversion is Attenuated in Schizophrenia

Ambiguity Aversion is Attenuated in Schizophrenia

Researchers conducted an fMRI study of decision-making under conditions of risk and ambiguity in patients diagnosed with schizophrenia.

Effort Allocation Influences Upon Cognition in Schizophrenia

Effort Allocation Influences Upon Cognition in Schizophrenia

Researchers studied social cognition and social problem solving in patients with schizophrenia by employing a validated test designed to assess emotion recognition abilities.

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

Delusions in Schizophrenia Associated With Myelin Abnormalities, Neuroinflammation

Study provides further evidence for the effects of white matter fiber abnormalities and neuroinflammation on positive symptoms in patients with schizophrenia.

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

White Matter Abnormalities and Clinical Symptom Severity in Schizophrenia

New findings provide an insight about the association between white matter microstructure and the severity of schizophrenia clinical symptoms.

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

Interaction of Proline and COMT Genotype Influences Negative Symptoms in Schizophrenia & Bipolar Disorder

The authors explored whether valproate (VPA) treatment effects vary by catechol-O-methyltransferase (COMT) genotype.

Neuroimaging of Schizophrenia: The Importance of Illness Severity and Duration

Neuroimaging of Schizophrenia: The Importance of Illness Severity and Duration

Researchers used voxel-based morphometry, which allows examination on a voxel-wise basis across the whole brain, to assess whether structural abnormalities in schizophrenia are static or progressive.

mPFC Abnormalities Associated With Social Cognition Deficits in Schizophrenia

mPFC Abnormalities Associated With Social Cognition Deficits in Schizophrenia

Poor psychosocial functioning among individuals diagnosed with schizophrenia is associated with deficits in social cognition.

Neuroinflammation in Schizophrenia: New PET Brain Imaging Studies

Neuroinflammation in Schizophrenia: New PET Brain Imaging Studies

TSPO expression is frequently used as a biomarker for brain inflammation during PET imaging.

Clinical, But Not Subclinical, Psychosis Linked with Less Physical Activity

Clinical, But Not Subclinical, Psychosis Linked with Less Physical Activity

Low physical activity was defined as less than 150 minutes of moderate-to-vigorous exercise per week.

A Potential Biomarker for the Onset of Psychosis in High-risk Individuals

A Potential Biomarker for the Onset of Psychosis in High-risk Individuals

Researchers used the auditory mismatch negativity (MMN) paradigm to evaluate its potential as a neurophysiological biomarker for psychosis.

Poorly Organized Fiber Tracts in Patients With Schizophrenia

Poorly Organized Fiber Tracts in Patients With Schizophrenia

Investigators examined the white matter tracts in patients diagnosed with the schizophrenia with predominantly negative symptoms.

Cannabinoid Receptor System Dysregulation in Schizophrenia

Cannabinoid Receptor System Dysregulation in Schizophrenia

Researchers explored the role of the dysregulated cannabinoid receptor system in patients diagnosed with schizophrenia.

How Reliable Are Patient-reported Outcomes in Schizophrenia?

How Reliable Are Patient-reported Outcomes in Schizophrenia?

The primary outcome in this study was reliability of patient-ratings on subjective well-being.

Personalized Treatment With Second vs. First Generation Antipsychotics

Personalized Treatment With Second vs. First Generation Antipsychotics

The primary outcome in this study was the change in total quality-of-life scores from baseline to week 24 after patients were randomly assigned to a treatment group.

Cognition and White Matter Alterations in Schizophrenia, Bipolar Disorder

Cognition and White Matter Alterations in Schizophrenia, Bipolar Disorder

Direct comparison of white matter tracts between individuals with schizophrenia or bipolar disorder has not been performed to date.

Psychosocial and Demographic Predictors of Depression Among Individuals With Bipolar Disorder and Schizophrenia

Psychosocial and Demographic Predictors of Depression Among Individuals With Bipolar Disorder and Schizophrenia

Bipolar disorder and schizophrenia are characterized by significant genetic overlap, as well as significant clinical presentation overlap.

Typical Brain Maturation Reveals Clues to Clinical Manifestation of Psychiatric Disorders in Adolescence

Typical Brain Maturation Reveals Clues to Clinical Manifestation of Psychiatric Disorders in Adolescence

The authors examined measurements of cortical thickness and intracortical magnetization transfer (MT), a validated MRI marker for myelination, over time with regards to genomic patterning.

Polygenic Schizophrenia Risk Score Linked with Hippocampal Volume and Psychosis Status

Polygenic Schizophrenia Risk Score Linked with Hippocampal Volume and Psychosis Status

Previous studies comparing the hippocampal volume of at-risk mental state (ARMS) and first-episode psychosis (FEP) patients have produced mixed findings.

Cortical Molecular Markers Differentiate Psychotic, Bipolar Disorders

Cortical Molecular Markers Differentiate Psychotic, Bipolar Disorders

The researchers quantified the transcript levels of GAD67, parvalbumin, somastatin, and Lhx6 in the prefrontal cortex.

Can A Risk Calculator Predict Conversion to Psychosis?

Can A Risk Calculator Predict Conversion to Psychosis?

The researchers referred to their risk calculator as "well-performing."

Novel Candidate Biomarker Identified for Schizophrenia

Novel Candidate Biomarker Identified for Schizophrenia

Whereas the expression levels of CDK4 and MCM7 were significantly decreased only in the acute state, POLD4 was significantly decreased in the acute and remission states in the patients diagnosed with schizophrenia.

Longer Untreated Psychosis in Youth Associated With Worse Outcomes

Longer Untreated Psychosis in Youth Associated With Worse Outcomes

So far, the clinical presentation of psychosis in childhood and adolescence has only been examined in a small number of studies which are limited by small sample sizes.

Common Meds Increase Hospitalization for Dehydration, Heat-Linked Illness

Common Meds Increase Hospitalization for Dehydration, Heat-Linked Illness

Commonly used medications have been linked to an increased risk of hospitalization for dehydration and heat-related illness.

Prevalence of Antipsychotic Polypharmacy at 12%

Prevalence of Antipsychotic Polypharmacy at 12%

A diagnosis of schizophrenia and a length of stay of 90 days or more are the strongest predictors of polypharmacy.

Smoking Reduction Linked to Reduced Suicidality in Patients With Psychotic Conditions

Smoking Reduction Linked to Reduced Suicidality in Patients With Psychotic Conditions

At 12 months, researchers found a significant association between smoking reduction and suicidality.

Sign Up for Free e-newsletters